RT Conference Proceedings
T1 Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations
A1 Siefker-Radtke, A. O.
A1 Loriot, Y.
A1 Siena, S.
A1 Beato, C.
A1 Climent Duran, M. A.
A1 Varlamov, S.
A1 Duran, I.
A1 Tagawa, S. T.
A1 Geoffrois, L.
A1 Mellado, B.
A1 Semenov, A.
A1 Delva, R.
A1 Lykov, A. P.
A1 Dirix, L. Y.
A1 Akapame, S.
A1 O'Hagan, A.
A1 Tammaro, M.
A1 Mosher, S.
A1 Kang, T. W.
A1 Moreno, V.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/27557
UL https://hdl.handle.net/10668/27557
LA en
DS RISalud
RD Apr 11, 2025